AAV vector analysis reduces sample consumption to one-twentieth and improves the empty-capsid quantification limit
Background: Sample burden in capsid-loading analysis
Analysis of adeno-associated virus (AAV) gene therapy vectors may be able to use less sample while improving the limit of quantification for empty capsids. The researchers examined data-processing procedures and sample conditions for sedimentation velocity analytical ultracentrifugation (SV-AUC). The abstract concludes that total sample consumption could be reduced to one-twentieth of the conventional amount, although some limitations apply.
Capsid genome-loading status is a key analytical target in AAV development and production. With capsid-specific extinction coefficients, multiwavelength SV-AUC can determine the relative proportions of empty, partially filled, and full capsids. Sample consumption, however, is a burden. The conventional conditions cited by the researchers use 400 µL at approximately 9×10¹² viral particles/mL. Using this much material for analysis can also increase costs.
Key findings: Better quantification limits and sample savings are separate results
The researchers analyzed AAV at three wavelengths and compared the limit of quantification (LOQ) under different data-processing procedures. With standard SEDFIT analysis, the LOQ for empty capsids was 7.7%. Using the GUSSI integration package or an automated SEDFIT procedure with a predefined integration range lowered it to 2.3%. This means lower proportions of empty capsids could be quantified. It does not mean that the precision of every measurement improved by the same factor, and the abstract provides no specific figure for improvement in the limit of detection (LOD).
In the sample-reduction experiments, concentration and volume were examined separately. The researchers tested the consistency of results when AAV particle concentration was reduced to as little as one-fiftieth of the standard concentration and when sample volume was reduced to one-third. They reported that measurements using less sample still yielded reliable values for key metrics, including empty- and full-capsid content and AAV concentration.
The scope of these tests should be distinguished from the overall conclusion. The abstract states that total sample consumption could be reduced to one-twentieth of the conventional amount. This does not mean a reduction to one-hundred-and-fiftieth obtained by multiplying the maximum reduction factors for concentration and volume, nor does it mean that volume alone was reduced to one-twentieth. The specific combination of conditions that achieved this level of sample savings, and the details of the remaining limitations, are not available in the abstract provided.
Implications and outlook: Obtaining key measurements from less sample
The study’s main contribution is to show that adjusting SV-AUC data-processing procedures and sample conditions may improve the empty-capsid LOQ and reduce sample consumption. The findings may be useful to analytical teams assessing capsid-loading status in AAV samples available only in limited quantities. However, there is insufficient evidence to conclude that all quality metrics measured under low-sample conditions are equivalent to those obtained under standard conditions.
The materials reviewed were the paper’s bibliographic information and abstract in the Journal of Pharmaceutical and Biomedical Analysis. The full text is needed to verify the actual wavelengths, number of replicate measurements, statistical validation, and detailed limitations of the low-sample conditions. The abstract also does not report validation of real-time quality control on a production line or reduced analysis time. The study suggests a possibility for reducing sample burden, but it does not assess whether treatment costs decrease or patient safety improves.
The main findings are available in the paper abstract indexed by Europe PMC.
Production and development of adeno-associated viruses (AAV) for gene therapy applications requires sophisticated analytical methods to assess critical quality attributes of the product. A popular method providing relevant information on the loading status of the AAV capsid is sedimentation velocity analytical ultracentrifugation (SV-AUC). While multiwavelength SV-AUC, used along with extinction coefficients for different capsid species, delivers the relative percentages of empty, partially and filled AAV capsids, it does so at the cost of high sample consumption (typically 400 µl at ∼9*10
When an AAV development team needs to assess capsid-loading status in a limited sample, this study provides a basis for considering both SV-AUC sample conditions and data-processing procedures. For example, before adopting low-sample conditions, an analytical team could compare empty- and full-capsid content and AAV concentration results against those obtained under standard conditions, and check whether the empty-capsid LOQ is adequate for its purpose. This is a proposed application based on the findings, not a reported implementation. Sample savings and LOQ improvement should be validated separately. Because the abstract does not provide enough detail to reproduce the conditions and limitations associated with reducing sample consumption to one-twentieth, the scope of application should be assessed after reviewing the detailed conditions in the full text.